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Abstract
External quality assurance for serological detection of chikungunya
virus infection was performed to assess the diagnostic quality of
expert laboratories. Of 30 participants, only six correctly analysed
all reference samples with their respective tests. Thirteen
laboratories gave at least 85% correct results, and 11 laboratories
75% or less. IgM antibodies were detected less frequently than IgG
antibodies (p <0.001). The study provides information on the
quality of different serological tests and indicates that most of the
participants need to improve the sensitivity of their assays, in
particular to detect IgM antibodies more reliably and be able to
detect acute infections adequately.
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Chikungunya virus (CHIKV), an alphavirus of the family Toga-
viridae, received considerable attention during its last major
outbreaks in the Indian Ocean region, India and Southeast
Asia in 2005–2006. It is transmitted to humans by Aedes
mosquitoes. The infection is characterized by sudden onset
of fever, skin rash and severe arthralgia, sometimes persisting
for several months. Currently, there is no effective antiviral
treatment, but symptoms are generally self-limiting [1–5]. In
summer 2007, the ﬁrst autochthonous CHIKV outbreak in
Europe was reported from north-eastern Italy [6]. As Aedes
albopictus has been introduced into several European coun-
tries, fears exist that viral transmission could also resurge in
other countries, because of the introduction of viraemic
persons from endemic areas and ecological factors [7].
Reliable laboratory diagnostics are required for detection of
imported cases, and early recognition of local transmission
to strengthen surveillance and timely vector control. During
CHIKV infections, IgM and IgG antibodies can be detected
shortly after the onset of symptoms [8] both by in-house
assays and by the few existing commercial assays [1,9]. How-
ever, the sensitivity and speciﬁcity of these tests have been
poorly assessed, and the possibility of false-positive reactions
resulting from cross-reactivity with other arboviruses should
be excluded.
We present the results of the ﬁrst external quality assur-
ance (EQA) study on CHIKV serology to assess the diagnos-
tic accuracy of laboratories and procedures. Thirty expert
laboratories from 23 countries participated in this study,
announced as EQA on diagnostic proﬁciency, run by the
European Network for diagnostics of ‘Imported’ Viral Dis-
eases, and including publication of the results in a compara-
tive and anonymous manner. Test samples were generated
by diluting well-characterized human sera with fresh frozen
plasma negative for human immunodeﬁciency virus, hepatitis B
virus and hepatitis C virus. After dilution, the enriched
serum samples were heat-inactivated (56C, 1 h), frozen, and
lyophilized in aliquots of 100 lL. Proﬁciency panels consisted
of ten reference samples. As positive controls, aliquots of six
samples from three selected sera positive for antibodies
against CHIKV (including a two-fold dilution series of one
antiserum: samples 12, 11, 2 and 4) were provided. For spec-
iﬁcity controls, aliquots of two antisera containing antibodies
reactive with heterologous arboviruses (dengue virus and
West Nile virus), approved in past EQA panels [10,11], were
included. Two aliquots from conﬁrmed seronegative samples
served as negative controls. Before shipment, two EQA
panel sets were tested by two reference laboratories in our
network, to conﬁrm the quality of the samples after prepara-
tion. Participants were asked to analyse the material by the
diagnostic methods that they routinely use for serological
detection of CHIKV. Information was requested concern-
ing the method type/format, e.g. enzyme immunoassay,
haemagglutination inhibition assay or immunoﬂuorescence
assay, and whether it was an in-house assay or commercial
kit. The following criteria were selected as minimum require-
ments for successful overall proﬁciency, scored with 20
points (= 100%). First, laboratories had to detect the six
CHIKV-reactive samples correctly for both IgM (if tested)
and IgG antibodies. Second, neither antisera containing
cross-reactive antibodies to heterologous arboviruses nor
negative samples should give a positive result. Equivocal or
borderline results were treated as positive. False-positive or
false-negative results were not scored. Differentiation
between IgM and/or IgG results was considered separately,
and gave additional information concerning diagnostic quality.
Collected data were analysed using SPSS 14.0 for Windows
(SPSS Inc., Chicago, IL, USA). Results were analysed using
the chi-square test. Whether or not common technical fac-
tors inﬂuenced the performance of participating laboratories
was assessed by logistic regression.
Only six of 30 participating laboratories achieved all crite-
ria for successful performance (Table 1). Thirteen laborato-
ries gave at least 85% of accurate results. Lack of sensitivity
for detection of IgM was observed for most laboratories
scoring below 18 points. For performance under 70%, even
the hypothesis of random expectation may not be ruled out.
Interestingly, laboratories using the same commercial assay
(Anti-Chikungunya virus IIFT IgM/IgG; Euroimmun AG) varied
strongly in diagnostic accuracy. As commercial assays are
produced according to certiﬁed criteria ensuring increased
reproducibility of the results [9], false storage or improper
handling of samples and assays is the most likely reason for
this variability. Only three laboratories (nos. 5, 31 and 37)
reported false-positive results on samples reactive for heter-
ologous arboviruses or seronegative samples. Overall, the
observed speciﬁcity was better than in past EQA studies
[10–12]. As dengue virus and CHIKV co-circulate in some
regions, causing similar clinical symptoms, differential diagno-
sis between these arboviral infections is very important.
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However, it should be noted that co-infections can be
detected in some patients [13]. Table 2 shows that the sensi-
tivity of IgM detection was signiﬁcantly lower than that of
IgG detection (p <0.001). These results clearly demonstrate
that either the assays have to be improved or that they were
not performed correctly. As described in previous EQA
studies [10–12], reliable assays for IgM detection are a prere-
quisite for correct diagnosis of acute or recent infections,
and their development is therefore crucial. Thirteen labora-
tories used commercial tests (12 used Anti-Chikungunya
virus IIFT IgM/IgG, Euroimmun AG; one used Chikungunya
IgM Rapid Test, CTK Biotech Inc.) and 19 laboratories used
in-house tests. In agreement with previous studies [10–12],
no signiﬁcant variation was found when comparing either
assay type/format (enzyme immunoassay vs. immunoﬂuores-
cence assay vs. haemagglutination inhibition assay) or assay
origin (in-house assay vs. commercial assay) (data not
shown).
This is the ﬁrst multicentre EQA study of CHIKV serology
to evaluate laboratory proﬁciency, indicating a need for cer-
tain laboratories to improve their test practice, in particular
the detection of IgM antibodies. The great variation in the
performance of different laboratories is similar to that
observed in previous EQA studies [10–12]. Several laborato-
ries recently and rapidly implemented CHIKV diagnostic
assays, which may explain the great variability. However, for
the clinical management of travellers returning from endemic
areas to their non-endemic homelands, where pre-existing
antibodies for alphaviruses are unlikely, the detection of IgG
is considered to be a valid indicator of CHIKV infection [14].
For detecting acute cases, IgM provides only limited addi-
tional sensitivity. The lack of sensitivity in IgM detection may
be compensated by simultaneous PCR testing. Comparative
testing of well-characterized samples provided all participants
with the opportunity to identify weaknesses and to improve
methodologies, which should be conﬁrmed in subsequent
studies. New improved assays should detect the avidity of
IgG to discriminate between acute primary and past infec-
tions in endemic countries, as IgM can persist for more than
1 year [9].
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Laboratories Participating in the EQA
Study
The following 30 laboratories participated in the EQA study.
Europe/Middle East: Medizinische Universita¨t Wien, Vienna,
Austria; Institute of Tropical Medicine, Antwerpen, Belgium;
National Reference/WHO Collaborative Centre for Arbovi-
ruses & Haemorrhagic Fevers, Institut Pasteur, Lyon, France;
Unite des Virus Emergents, Hopital La Timone, Marseille,
France; CIBU Institut Pasteur, Paris, France; Bernhard Nocht
Institut, Hamburg, Germany; EUROIMMUN AG, Lu¨beck,
Germany; National Virus Reference Laboratory, University
College Dublin, Dublin, Ireland; St Orsola University Hospital
of Bologna, Bologna, Italy; Istituto Nazionale per le Malattie
Infettive, Rome, Italy; Istituto Superiore di Sanita`, Rome,
Italy; Norwegian Institute of Public Health, Oslo, Norway;
Instituto Nacional de Sau´de Dr Ricardo Jorge (INSA), Lisboa,
Portugal; University of Ljubljana, Ljubljana, Slovenia; National
Centre for Microbiology, Majadahonda (Madrid), Spain;
Swedish Institute for Infectious Disease Control, Solna, Swe-
den; University Hospitals of Geneva, Geneva, Switzerland;
Spiez Laboratory, Spiez, Switzerland; Rijksinstituut voor
Volksgezondheid (RIVM), Bilthoven, The Netherlands; Eras-
mus University Rotterdam, Rotterdam, The Netherlands;
Pasteur Institute of Iran, Teheran, Iran; National Center for
Zoonotic Viruses, Cahim Sheba Medical Centre, Tel Hasho-
mer, Israel; Special Infectious Agents Unit, King Abdulaziz
University Hospital, Jeddah, Kingdom of Saudi Arabia. Asia:
Public Health Laboratory Centre, Hong Kong; National
Institute for Infectious Diseases, Tokyo, Japan; National
Environmental Health Institute, Singapore. The Americas:
TABLE 2. Evaluation of the anti-chikungunya virus (CHIKV)-
positive samples in the test panela
Sample no.
Expected
result, IgM/IgG
Fraction of
correct classiﬁed
results for IgM (%)
Fraction of
correct classiﬁed
results for IgG (%)
12 +/+ 69.6 (16) 100.0 (23)
11 +/+ 43.5 (10) 100.0 (23)
2 +/+ 30.4 (7) 91.3 (21)
4 +/+ 21.7 (5) 82.6 (19)
10 +/+ 69.6 (16) 100.0 (23)
5 +/+ 69.6 (16) 95.7 (22)
Overall +/+ 50.7b 94.9
aNo. of laboratories, 23. Number of laboratories with correct results shown in
parentheses.
bIgM antibodies are detected less frequently than IgG antibodies (v2 = 68.1;
p<0.001).
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Public Health Agency of Canada, Winnipeg Manitoba, Can-
ada; Institut Pasteur de la Guyane, Cayenne, French Guiana.
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